Journal
JOURNAL OF PERSONALIZED MEDICINE
Volume 12, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/jpm12050685
Keywords
EGFRvIII; glioblastoma; female; VEGF; trial population
Funding
- Associazione Italiana per la Ricerca sul Cancro [IG 23154]
Ask authors/readers for more resources
The prognostic role of EGFRvIII in glioblastoma is controversial. However, this study found no association between EGFRvIII and worsened prognosis. Interestingly, female sex was found to be associated with better outcomes.
The prognostic role of epidermal growth factor receptor variant III (EGFRvIII), a constitutively activated oncogenic receptor, in glioblastoma is controversial. We performed a prospective study enrolling 355 patients operated on for de novo glioblastoma at a large academic center. The molecular profile, including EGFRvIII status, MGMT promoter methylation, and VEGF expression, was assessed. Standard parameters (age, clinical status and extent of surgical resection) were confirmed to hold prognostic value. MGMT promoter methylation portended a slightly improved survival. In the whole series, confirming previous results, EGFRvIII was not associated with worsened prognosis. Interestingly, female sex was associated with a better outcome. Such findings are of interest for the design of future trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available